Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of SC-101 in NECTIN4 gene amplification–positive advanced solid tumors
ChiCTR2600128129Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jul 2026
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SC-101 in Non-hematologic malignancy, triple-negative breast cancer (TNBC), breast cancer and 3 more, sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective Response Rate. Started Jul 2026; status: recruiting.
02
Drugs
SC-101
03
Conditions
Non-hematologic malignancytriple-negative breast cancer (TNBC)breast cancerpancreatic cancer (PC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600128129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128129.